frequently relapsing nephrotic syndrome with sensitivity to steroid. Nephrotic syndrome with minor glomerular abnormality
Conditions
Interventions
Intervention 1: Intervention group: One 5-mg Montelucast pill (produced by Abidi-pharma company under Airokast brand name) is prescribed daily for one month with 1 mg/kg Prednisolone. Intervention 2:
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 15 Years
Inclusion criteria
Inclusion criteria: Patients with frequently relapsing nephrotic syndrome ( 4 times or more in a year) sensitivity to steroid ( proper response to treatment with oral Corticosteroid with dosage of 1-2 mg/kg in a patient)
Exclusion criteria
Exclusion criteria: extreme edema resistance to treatment with Corticosteroid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of urine protein to creatinine. Timepoint: before and one month after the beginning of treatment. Method of measurement: biochemical test.;Serum Albumin. Timepoint: before and one month after the beginning of treatment. Method of measurement: biochemical test.;Creatinine. Timepoint: before and one month after the beginning of treatment. Method of measurement: biochemical test.;Cholesterol. Timepoint: before and one month after the beginning of treatment. Method of measurement: investigation in laboratory.;Short term rate of recovery. Timepoint: one month after the beginning of treatment. Method of measurement: clinical observation.;Complications. Timepoint: one month after the beginning of treatment. Method of measurement: clinical observation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSahar Malaekeh
Mashhad University of Medical Sciences
Outcome results
None listed